EntityRisk
- Company typePrivate
- Founded2013
- HeadquartersPrinceton, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
EntityRisk firmographics
Firmographics- Name
- EntityRisk
- Legal name
- EntityRisk
- Website
- https://entityrisk.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
EntityRisk industry classification
Industry- Product category
- Health Economics Software / HEOR Analytics Platform
- NAICS
- Software Publishers (51321), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)
Keywords
Where EntityRisk is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Markets served
EntityRisk business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Platform Licensing/Subscription: PROVEN platform delivered as software-as-a-service to biopharma companies for health economic modeling, pricing analysis, and evidence generation. Likely subscription-based model given enterprise B2B nature.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
EntityRisk product offering
Product offeringCore offering
EntityRisk sells PROVEN™, a software-as-a-service platform that integrates health economics and policy expertise with machine learning and Bayesian methods to predict real-world health outcomes, simulate value-based pricing, prioritize evidence-generation investments, and forecast commercial revenue for biopharmaceutical products. The platform comprises five ML modules (OutcomesML™, ValueML™, EvidenceML™, PriceML™, CommercialML™) and is delivered to biopharma companies, biotech firms, healthcare investors, and diagnostics companies via enterprise subscriptions.
Product overview
EntityRisk offers PROVEN™ as a unified, modular software platform for health economics and outcomes research. The platform consists of five specialized ML modules—OutcomesML™, ValueML™, EvidenceML™, PriceML™, and CommercialML™—that work together to provide comprehensive health outcome predictions, value-based pricing simulations, evidence quantification, price forecasting, and revenue projections. Built on Python with a modular architecture, PROVEN™ integrates clinical trial data, real-world data, and financial data to generate probabilistic predictions for biopharma decision-making.
Differentiator
Problem solved
Functional benefit
Products and services
- PROVEN™ Platform Advanced health economic modeling software platform built on a Python core with modular design that uses machine learning and Bayesian methods to predict health outcomes, identify value-based pricing, and substantiate evidence-generation investments for biopharma companies and healthcare investors.
- OutcomesML™ Module of PROVEN™ that predicts the distribution of real-world health outcomes for pipeline or marketed products from clinical trial data (including surrogate endpoints and biomarkers), real-world data, and/or target product profiles (TPPs).
- ValueML™ Module of PROVEN™ that simulates a full array of justifiable value-based prices, budget impact, and cost-effectiveness outcomes using multiple value-assessment frameworks simultaneously to support pricing strategies, payer negotiations, and HTA submissions.
- EvidenceML™ Module of PROVEN™ that directly links evidence to impact and quantifies the elasticity and risk surrounding product or population characteristics to prioritize evidence investments, optimize trial design, and establish and update TPPs and product forecasts.
- PriceML™ Module of PROVEN™ that predicts the likely distribution of real-world WAC and net prices for any given target product profile.
- CommercialML™ Module of PROVEN™ that forecasts long-term revenues and downside risks over a product lifecycle across pricing, contracting, efficacy, and competitive scenarios.
Quantifiable outcome
- Base-case value-based price 84% higher vs ICER assessments
- +4 more outcomes
Companies that use EntityRisk
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
EntityRisk technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
EntityRisk partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cleo DiagnosticscorePartnership with Cleo Diagnostics to provide evidence-based insight into the economic value of Cleo's Ovarian Cancer Pre-Surgical Test in the U.S. market. EntityRisk is conducting a health economic study to support U.S. market entry.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
EntityRisk competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Customer concentration
EntityRisk social profiles
Digital presenceEntityRisk financial estimates
Financial estimateRevenue estimate
Valuation estimate
EntityRisk leadership team
Management profileNumber of profiles
Profiles20 records
EntityRisk funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EntityRisk M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EntityRisk
What does EntityRisk do?
EntityRisk sells PROVEN™, a software-as-a-service platform that integrates health economics and policy expertise with machine learning and Bayesian methods to predict real-world health outcomes, simulate value-based pricing, prioritize evidence-generation investments, and forecast commercial revenue for biopharmaceutical products. The platform comprises five ML modules (OutcomesML™, ValueML™, EvidenceML™, PriceML™, CommercialML™) and is delivered to biopharma companies, biotech firms, healthcare investors, and diagnostics companies via enterprise subscriptions.
Is EntityRisk a public or private company?
EntityRisk is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EntityRisk founded?
EntityRisk was founded in 2013. It employs 11 to 50 people.
Where is EntityRisk based?
EntityRisk is headquartered in Princeton, United States, in the North America region.
How does EntityRisk make money?
One revenue line is on record: software Platform Licensing/Subscription.
Does EntityRisk have an API?
No public API is recorded for EntityRisk.
What industry is EntityRisk in?
EntityRisk's product category is Health Economics Software / HEOR Analytics Platform. Its primary akta.pro industry code is HLAIAKAC, Value Dossier & Evidence Generation (AMCP/Global Value Dossier), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 51321 and its SIC code is 8731.